Pharma News

Artemisinin-ALA co-treatment could kill cancer cells and suppress tumour growth with fewer side effects

Artemisinin, a potent anti-malarial drug, has been widely hailed as a promising alternative cancer treatment. Scientists from the National University of Singapore (NUS) recently showed that its anti-cancer properties could be enhanced by 10 folds when used in combination with Aminolaevulinic acid (ALA), a photosensitiser or a drug which, upon exposure to light, leads to generation of free radicals that can kill cells.

Congenital hyperinsulinism is a serious yet poorly understood condition. Research funded by the Swiss National Science Foundation has discovered how it is caused by a genetic mutation.

Ipsen announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental indication for Somatuline® Depot (lanreotide) Injection 120 mg for the treatment of carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analogue rescue therapy.

Myriad Genetics, Inc a leader in molecular diagnostics and personalized medicine, announced that two important studies will be featured in podium presentations at the 36th annual conference of the National Society of Genetic Counselors (NSGC) in Columbus, OH.

[adsense:336x280:8701650588]

AstraZeneca announced full results from the EXSCEL (EXenatide Study of Cardiovascular Event Lowering) trial that showed cardiovascular safety with Bydureon (exenatide extended-release) in patients with type-2 diabetes (T2D) at a wide range of CV risk.

Pharma Major Lupin announced that it has received final approval for its Metronidazole Tablets USP, 250 mg and 500 mg from the United States Food and Drug Administration (FDA) to market a generic version of G.D. Searle LLC's Flagyl® Tablets, 250 mg and 500 mg.

Ramucirumab plus docetaxel improves progression-free survival in patients with advanced or metastatic urothelial cancer who have progressed on platinum-based chemotherapy, according to late-breaking results from the phase III RANGE trial presented at the ESMO 2017 Congress in Madrid  to be published in The Lancet.

The Zika virus (ZIKV) may infect and kill a specific type of brain cancer cells while leaving normal adult brain tissue minimally affected, according to a new study supported by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health. In the paper, published online on September 5 in The Journal of Experimental Medicine, researchers describe the impact of ZIKV on glioblastoma cells in both human tissue samples and mice.

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Propafenone Hydrochloride Extended-Release Capsules USP, 225 mg, 325 mg, and 425 mg, the generic version of Rythmol SR® Capsules, 225 mg, 325 mg, and 425 mg, of GlaxoSmithKline, LLC.

Panacea Biotec, India's highly progressive research based health management Company, has expanded its existing collaboration with Apotex Inc., the largest Canadian-owned pharmaceutical company, for sales & distribution of Prasugrel 5mg and 10mg tablets (generic version of Eli Lilly's Effient) in the USA.